A26Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT):
Bighin, C., Poggio, F., Dozin, B., Ceppi, M., Bruzzi, P., D'Alonzo, A., Giraudi, S., Levaggi, A., Lambertini, M., Miglietta, L., Vaglica, M., Fontana, V., Iacono, G., Pronzato, P., Del Mastro, L.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv336.26
Date:
October, 2015
File:
PDF, 33 KB
english, 2015
File converter
More search results
More benefits 
